Navigation Links
Presentation at Bio Contact Quebec 2007


MONTREAL, Oct. 2 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX:HAE), a specialty bio-therapeutics company developing high-value human proteins, announces that Mr. Joseph Galli, Chairman and Chief Executive Officer, will be presenting at BioContact Quebec 2007. Mr. Galli will be speaking on Wednesday, October 3, 2007 at 16:30 in the Bellevue Room, Chateau Frontenac in Quebec City.

About BioContact Quebec 2007

BioContact Quebec 2007 ( is a biopharmaceutical partnership symposium gathering over 1200 participants. More than 150 biopharmaceutical companies, coming from Canada, the United States, Asia and Europe, will be presenting in different sectors of activities (diagnostics, therapeutics and services) and disciplines such as cancer, cardiology, drug delivery systems, endocrinology, genomics/proteomics, immunology/infectiology, neurobiology, virology and medical technologies.

About Haemacure

Haemacure Corporation is a specialty bio-therapeutics company developing high-value human therapeutic proteins for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical hemostats.

Haemacure's lead product candidate, Hemaseel(TM)HMN, is a human-derived fibrin sealant in late-stage clinical development. Haemacure's second product candidate is human thrombin, a component of its fibrin sealant. Both candidates have applications in the expanding bio-surgical market. Follow-on development will focus on surgical hemostats, biomaterial combinations and drug delivery in select therapeutic areas. Haemacure has recently discovered additional specialty proteins in its plasma-derived intermediates and will advance these specialty proteins through partnerships with other pharmaceutical and biotechnology companies.

Forward-looking Statements

Certain statements contained in this news release and oral statements made by representatives of Haemacure that are not historical facts may be considered forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the biotech industry, changes in the regulatory environment in the jurisdictions in which Haemacure Corporation does business, stock market volatility, fluctuations in costs, the ability of Haemacure to set up its planned manufacturing facility, the completion and outcome of clinical studies as well as the development of new products, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Haemacure Corporation disclaims any intention or obligation to update these statements.

Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Onchocerciasis: Presentation And Treatment
2. Researchers Warn That Routine Physical Examination Could Miss Breech Presentation
3. Implantable Contact Lens Found Safe and Effective
4. Contact Lenses Found To Slow Progression Of Myopia in Kids
5. Reduce eye infection through new-age contact lenses
6. New contact lens materials
7. Newborns Know how to make eye contact
8. Contact Lenses Implicated in Fungal Infections
9. Headway in identification of allergens of contact dermatitis
10. Alarm Raised for Contact Lens Wearers
11. Contact Lens Care Products Results In Eye Infection
Post Your Comments:
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 27, 2016  VMS Rehab Systems, Inc. ( ... whatever measures required to build a strong and stable ... currently listed on the OTC Markets-pink current trading platform. ... CEO, "We are seeing an anomaly in market trading ... only by the Company, but shareholders and market players ...
(Date:6/24/2016)... N.C. , June 24, 2016  Consumers ... decisions and regulators/payers have placed more emphasis on ... environment, patient support programs in the pharmaceutical industry ... patients, medications. Consequently, pharmaceutical companies are focusing on ... they are providing products and services that improve ...
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
Breaking Medicine Technology: